A Legal Door Opens for Six Peptides — While the Evidence Gets Graded
Issue #16 · November 1, 2026
Before Surgery, Tell Them About Your GLP-1. A 47,000-Patient Study Shows Why.
Fasting rules assume the stomach empties on schedule. On GLP-1s it may not. New UK data put regurgitation risk at 11 times baseline — and anaesthetists say patients keep it secret.
Read →
Hair Loss on a GLP-1: The Trials Say 4%. The Surveys Say 70%. Both Numbers Are Real.
Trials code hair loss in 3-7% of people on semaglutide or tirzepatide. One real-world survey put it at 70%. Both numbers are correct, they measure different things, and the gap explains why the shedding happens.
Read →
Six Peptides Just Got a Legal Path Into U.S. Pharmacies. It Isn't Approval.
HHS told FDA not to enforce its peptide rules for six compounds: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Pharmacies can compound them under ten conditions. This is not approval, and FDA's own scientists opposed it.
Read →
BPC-157 Has 150+ Animal Studies. The First Systematic Review of the Human Evidence Found 3 Trials, 30 People.
A prospectively registered systematic review just graded every human study of BPC-157. It found three trials, thirty people, and a very low certainty rating. Here is what that means if you are weighing the peptide.
Read →
Are Peptides Legal in 2026? What Actually Changed (and What Didn't)
No research peptide is FDA-approved for human use, and none of the popular ones has a federal pathway a pharmacy can use today. The policy that would open a temporary door has been sitting unpublished at the White House since 14 October 2026.
Read →
GLP-1 Drugs Cut Fractures but Lower Bone Density. Both Findings Are Real.
Large real-world data say GLP-1 drugs reduce fragility fractures. The randomized bone-density trials say they pull density out of skeleton. Here is why both are true, and what it means for your bones.
Read →
Epitalon Is Sold on Telomere Science. The New Review Found Four Human Studies.
Epitalon is marketed as a telomere-lengthening longevity peptide. A new Johns Hopkins-led review counted every human study ever published: there are four. Here is what they showed, and why FDA's own scientists opposed compounding it.
Read →
This week the newsletter writes itself in two columns: policy and evidence. On the policy side, HHS quietly told the FDA to stop enforcing its peptide compounding rules for six compounds — BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 — opening a legal path for pharmacies to compound them under ten conditions. On the evidence side, two prospectively registered systematic reviews did something the marketing never does: they counted the actual human studies behind BPC-157 and epitalon. Three trials and thirty people for one. Four studies for the other.
Those two columns collide in a useful way. A legal path is not a clinical endorsement, and the timing — human evidence for two of the six compounds best described as barely there — is exactly the kind of tension worth sitting with. The FDA's own scientists opposed the enforcement-discretion carve-out, and the ten conditions attached to it are stricter than most people realise. Legal, available and proven are three different things, and this week moved only the first.
We've also got the GLP-1 practicals readers ask about most: a 47,000-patient study on why you should tell your anaesthetist about your GLP-1 before surgery, the strange gap between trial data (4% hair loss) and real-world surveys (70%), and a genuinely counterintuitive bone story — GLP-1 drugs cut fractures while lowering bone density. Seven stories, one theme: the gap between what we assume and what the data actually say.
Before Surgery, Tell Them About Your GLP-1
The headline number from the new UK cohort is hard to ignore: across roughly 47,000 patients, GLP-1 use was associated with regurgitation risk around 11 times baseline during anaesthesia. The mechanism is not mysterious. GLP-1 receptor agonists — semaglutide, tirzepatide and, to a degree, retatrutide — slow gastric emptying as part of how they blunt post-meal glucose spikes. Pre-operative fasting rules assume the stomach empties on a predictable schedule. On a GLP-1, that schedule quietly stops applying.
The second finding is the one anaesthetists keep flagging: patients don't disclose. GLP-1s are often framed as lifestyle drugs, so people don't list them the way they'd list blood pressure medication. The practical implication is simple even if the science is complex — put the drug on your pre-op medication list, and expect guidance to shift toward longer fasting windows or gastric ultrasound screening before elective procedures. Aspiration pneumonia is rare but severe, and this is one of the few perioperative risks you can defuse with a single sentence at your pre-op appointment.
Hair Loss on a GLP-1: Why 4% and 70% Are Both Real
Trials code hair loss in 3–7% of people on semaglutide or tirzepatide. One real-world survey put the number at 70%. Both are correct because they measure different things. Trial adverse-event coding captures hair loss severe or notable enough to be recorded as a clinical event. Surveys capture any increase in shedding over months — including the diffuse, mild kind most people notice on the shower drain and never report.
The mechanism points to the weight loss, not the molecule. Rapid caloric deficit is a classic trigger for telogen effluvium: a physiological shock that pushes follicles from the growth (anagen) phase into the resting (telogen) phase roughly two to three months after the trigger. That lag is why people blame the pen they started last week when the real culprit is the eight kilos gone since spring. It also means the fix is structural rather than pharmaceutical — slower loss rates, adequate protein, and checking iron, zinc and vitamin D status — and that the shedding is usually reversible once the body stops treating weight loss like an emergency.
Six Peptides Get a Legal Path Into U.S. Pharmacies
The week's biggest story is regulatory. HHS instructed the FDA to exercise enforcement discretion for six compounds — BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 — meaning licensed pharmacies can compound them without the FDA pursuing enforcement action, provided ten conditions are met. For anyone who has been buying research-chemical grey-market vials, this is a supply-chain earthquake: pharmaceutical-grade sourcing, with sterility and potency testing, becomes a legal option for the first time.
Read the fine print twice. This is not approval — none of the six has been through a drug approval process, and enforcement discretion is a policy posture, not a safety determination. The FDA's own scientists reportedly opposed the carve-out on safety grounds, and the ten conditions (including prescribing-context and documentation requirements) are designed to keep this narrow. The honest framing: your vial just got cleaner and more traceable. Your evidence base did not change.
BPC-157: 150+ Animal Studies, 3 Human Trials
A prospectively registered systematic review — the first of its kind for BPC-157 — graded every human study ever published. The tally: three trials, thirty participants, and a very low certainty rating under GRADE. For context, BPC-157 is one of the most-discussed peptides online, with an animal literature exceeding 150 studies showing effects on tendon healing, gut integrity and angiogenesis — much of it built around proposed mechanisms involving VEGF signalling, nitric oxide pathways, and growth hormone receptor upregulation in fibroblasts.
What does very low certainty mean for someone weighing a cycle? It does not mean the peptide doesn't work — it means nobody has demonstrated in humans that it does, and with trials this small the confidence intervals are enormous. It cuts both ways on safety: thirty people can't detect rare harms either. If you run it, you're running it on mechanistic plausibility and animal data, and the review's value is making that trade explicit instead of letting marketing blur it.
Are Peptides Legal in 2026? What Actually Changed
Monday's explainer maps the whole landscape: no research peptide is FDA-approved for human use, and until this week none had a federal pathway a pharmacy could legally use. The policy that opened the door had been sitting unpublished at the White House since 14 October — which is precisely what changed on Friday. If the terminology feels slippery, that's by design: “research chemical, not for human use” labelling is a marketing workaround, not legal protection, and 503A/503B compounding rules are the actual gatekeepers of what a pharmacy can make.
The distinction worth carrying forward: legality, availability and evidence are three separate axes. This week moved the first, left the second mostly unchanged for individual buyers, and — as the BPC-157 and epitalon reviews show — barely touched the third.
GLP-1s Cut Fractures but Lower Bone Density. Both Are Real.
Large real-world datasets show GLP-1 users suffer fewer fragility fractures. Randomised bone-density trials show the drugs pull density out of the skeleton. The resolution is that fracture risk and bone mineral density are not the same measurement. Much of fracture risk is driven by falls, body weight and metabolic health — and GLP-1 drugs improve all three: less weight means less impact force, better glycaemic control means less microvascular damage to bone, and lower systemic inflammation helps normalise bone remodelling.
The density loss is real too — weight loss itself unloads the skeleton, and mechanical loading is a primary stimulus for bone formation. Add a caloric deficit and potential lean-mass loss and the density reductions in trials are unsurprising. For anyone on long-term therapy, the practical stack is boring and effective: resistance training (the single strongest behavioural signal for preserving density), protein at the higher end of normal, calcium and vitamin D sufficiency, and a DEXA baseline if you plan to stay on therapy for years. The drugs look net-positive for fracture risk so far — but net-positive is an average, and averages are made of individuals.
Epitalon: Four Human Studies, Zero Large Trials
Epitalon is sold on telomere science — the idea that a four-amino-acid peptide can lengthen telomeres and slow ageing. A new Johns Hopkins-led review counted every human study ever published. There are four, mostly small and older, largely from the Khavinson bioregulator research programme. That literature suggests biological activity worth studying; it does not establish telomere-mediated life extension in humans, and four studies is not a foundation for the claims on most product pages.
The review lands the same week epitalon was named in the HHS enforcement-discretion list — and the same week the FDA scientists' opposition to compounding it became public. The pattern across this issue is consistent: the legal door opened faster than the evidence did. That's not an argument against these compounds; it's an argument for using them with your eyes on the actual study counts.
What to Watch Next Week
Three threads to follow. First, the fine print of the enforcement-discretion conditions as pharmacies begin compounding — particularly the prescribing-context rules, which will determine who can actually get these six compounds and at what standard. Second, any FDA response, given its own scientists opposed the carve-out; policy postures can be revisited as quickly as they're issued. Third, perioperative guidance: the 47,000-patient aspiration study is the kind of paper that moves anaesthesia society statements within months, and the GLP-1 bone and hair questions will keep accruing as real-world cohorts mature. Expect the fracture-versus-density tension to get a definitive answer only when longer randomised extension data report.
Model This Week's Compounds in the BioStack Generator
This week's newsletter covered BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 on the regulatory side, with semaglutide, tirzepatide and retatrutide driving the GLP-1 stories. If you're designing a stack that mixes the newly legal compounds with a GLP-1 — or deciding what BPC-157's three-trial evidence base means for your actual dosing — the BioStack Generator models those interactions against your specific goals, dosing schedule and risk tolerance. It takes two minutes, and it forces the same discipline this week's reviews did: separate what's plausible from what's proven.